Affinity Asset Advisors LLC Decreases Holdings in Perspective Therapeutics, Inc. $CATX

Affinity Asset Advisors LLC trimmed its position in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 52.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,050,000 shares of the company’s stock after selling 1,174,196 shares during the quarter. Affinity Asset Advisors LLC owned 1.41% of Perspective Therapeutics worth $3,612,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of CATX. HighTower Advisors LLC lifted its holdings in Perspective Therapeutics by 13.2% in the first quarter. HighTower Advisors LLC now owns 201,586 shares of the company’s stock valued at $429,000 after acquiring an additional 23,475 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Perspective Therapeutics by 6.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company’s stock valued at $925,000 after purchasing an additional 27,119 shares during the last quarter. Nuveen LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $2,647,000. Federated Hermes Inc. purchased a new position in shares of Perspective Therapeutics in the first quarter worth approximately $288,000. Finally, Taylor & Morgan Wealth Management LLC boosted its holdings in shares of Perspective Therapeutics by 4.4% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 94,000 shares of the company’s stock worth $323,000 after buying an additional 4,000 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $2.40 on Friday. The business has a fifty day moving average of $2.92 and a 200 day moving average of $3.29. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $5.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million. Equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on CATX shares. BTIG Research initiated coverage on shares of Perspective Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Friday, October 3rd. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, November 11th. UBS Group restated a “buy” rating and issued a $7.00 price target (down previously from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. Finally, B. Riley decreased their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Four analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $11.50.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.